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1 |  INTRODUCTION
Noonan syndrome is still a challenging diagnosis as well as the 
diagnosis of nonimmune hydrops fetalis mainly because of ex-
tensive differential diagnosis. The success of identifying a cause 
depends on the thoroughness of efforts to establish a diagnosis.
Therefore, we developed the so-called hydrops panel, 
a virtual gene panel diagnostic tool for quick diagnosis of 
NIHF. The panel includes 119 genes which are associated 
with NIHF (Table 1). In a second step, a complete analysis 
can be performed by whole-exome sequencing (WES). This 
facilitates the diagnosis and thus the management of the un-
derlying disease.
Noonan syndrome (NS) is an autosomal dominant disor-
der with a prevalence of 1:1,000–2,500 live births (Tartaglia, 
Gelb, & Zenker, 2011). It is characterized by various major 
and minor anomalies such as congenital heart defects, facial 
anomalies, and short stature.
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Background: Nonimmune hydrops fetalis (NIHF) is still a challenging diagnosis. 
The differential diagnosis is extensive and the success of identifying a cause depends 
on the thoroughness of efforts to establish a diagnosis. For the early diagnosis of 
NIHF, a virtual gene panel diagnostic tool was developed. The female premature 
baby in question was delivered via emergency cesarean at 30 + 1 weeks of gesta-
tional age (GA) due to rapidly developing NIHF to a healthy mother. The family 
history was noncontributory.
Methods: DNA of the family was extracted and sequenced by the virtual hydrops 
panel with whole-exome sequencing.
Results: The hydrops panel revealed Noonan syndrome (NS) with a germline muta-
tion in PTPN11 c.218C>T (p.Thr73Ile).
Conclusion: The diagnosis of our patient was rapidly confirmed by the hydrops 
panel. The variant of c.218C>T (p.Thr73Ile) has not yet been described in literature 
relating to NIHF. Only a few case reports of this variant are known. This particular 
mutation is associated with Noonan syndrome, congenital heart defect and persistent 
thrombocytopenia. Few reveal juvenile myelomonocytic leukemia.
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PTPN11 (OMIM#176876; Protein–tyrosine phosphatase 
nonreceptor-type 11) mutations are found in up to 35% of all 
cases of sporadic juvenile myelomonocytic leukaemia cases, 
5%–10% of all cases of childhood myelodysplastic syndrome, 
7% of all cases of B-cell precursor acute lymphoblastic leu-
kaemia, in cases of pediatric and adult acute myelogenous 
leukemia (AML) and some solid tumors (Kratz, Niemeyer, & 
Castleberry, 2005). Germline mutations in the PTPN11 gene 
cause about half of all cases of NS (Araki et al., 2009). The mu-
tation c.218C>T (p.Thr73Ile) revealed in this case is a germline 
mutation, but it can also be found as a somatic one in sporadic 
juvenile myelomonocytic leukemia (Kratz et al., 2005).
The PTPN11 gene encodes for the cytoplasmatic tyrosine 
phosphatase named Src homology region 2- domain-contain-
ing phosphatase-2 (SHP-2) which plays an important role in 
mesodermal patterning (Tang, Freeman, O’Reilly, Neel, & 
Sokol, 1995), for example, limb development (Saxton et al., 
1997), hematopoietic cell differentiation (Qu et al., 1997), 
and semilunar valvulogenesis (Chen et al., 2000).
SHP2 contains different domains named N-SH2, C-SH2, 
and PTP (Keilhack, David, McGregor, Cantley, & Neel, 
2005). The mutation noted in this child was in the N-SH2 
domain. The N-SH2 domain acts as a molecular switch, acti-
vating and deactivating SHP-2. By binding the PTP domain, 
a stable intermolecular interaction deactivates SHP2 (auto-
inhibition; Martinelli, 2012). The c.218C>T (p.Thr73Ile) 
mutation causes a conformational change in the interaction 
region between the N-SH2 and the PTP domain, leading to a 
disruption of N-SH2 and PTP with a consecutive persistent 
activation of SHP2 which acts upstream of RAS (Rat sar-
coma, proto–oncogene) as gain of function (Chan & Feng, 
2007).
Until now a genotype–phenotype correlation in Noonan 
syndrome could not be established (Zenker et al., 2004).
In Noonan syndrome patients all causative genes encode 
signaling molecules within the RAS signaling pathway, which 
is a major contributor to carcinogenesis (Kratz, Rapisuwon, 
Reed, Hasle, & Rosenberg, 2011).
T A B L E  1  Hydrops panel
Gen Transcript OMIM DISEASE
ALG1 ENST00000262374.5 *605907 #608540 CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ik; CDG1K
AP3B1 ENST00000255194.6 *603401 #608233 HERMANSKY–PUDLAK SYNDROME 2; HPS2
ARSA ENST00000216124.5 *607574 #250100. METACHROMATIC LEUKODYSTROPHY; MLD
ARSB ENST00000264914.4 *611542 #253200 MUCOPOLYSACCHARIDOSIS TYPE VI; MPS6
ASAH1 ENST00000262097.6 *613468 #228000 FARBER LIPOGRANULOMATOSIS; FRBRL
BLOC1S3 ENST00000433642.2 *609762 #614077 HERMANSKY–PUDLAK SYNDROME 8; HPS8
BRAF ENST00000288602.6 *164757 #613706 Noonan
CALCRL ENST00000409998.1 *114190 New disease; Duncan et al. J.Exp.Med 2018 Vol.215 No.9
CBL ENST00000264033.4 *165360 #613563 NOONAN SYNDROME-LIKE DISORDER WITH OR WITHOUT JUVENILE 
MYELOMONOCYTIC LEUKEMIA; NSLL
CCBE1 ENST00000439986.4 *612753 #235510 HENNEKAM LYMPHANGIECTASIA-LYMPHEDEMA SYNDROME 1; HKLLS1
CLN3 ENST00000568224.1 *607042 #204200 CEROID LIPOFUSCINOSIS, NEURONAL, 3; CLN3
CLN5 ENST00000377453.3 *608102 #256731 CEROID LIPOFUSCINOSIS, NEURONAL, 5; CLN5
CLN6 ENST00000249806.5 *606725 #601780 CEROID LIPOFUSCINOSIS, NEURONAL, 6; CLN6
#204300 CEROID LIPOFUSCINOSIS, NEURONAL, 4A, AUTOSOMAL RECESSIVE; 
CLN4A
CLN8 ENST00000331222.4 *607837 #600143 CEROID LIPOFUSCINOSIS, NEURONAL, 8; CLN8
#610003 CEROID LIPOFUSCINOSIS, NEURONAL, 8, NORTHERN EPILEPSY 
VARIANT
CTNS ENST00000046640.3 *606272 #219800 CYSTINOSIS, NEPHROPATHIC; CTNS;
CTSA ENST00000372484.3 *613111 #256540 GALACTOSIALIDOSIS; GSL
CTSD ENST00000236671.2 *116840 #610127. CEROID LIPOFUSCINOSIS, NEURONAL, 10; CLN10
CTSK ENST00000271651.3 *601105 #265800 PYCNODYSOSTOSIS
DHCR7 ENST00000355527.3 *602858 #270400 SMITH–LEMLI–OPITZ SYNDROME; SLOS
DTNBP1 ENST00000338950.5 *607145 #614076 HERMANSKY–PUDLAK SYNDROME 7; HPS7
EBP ENST00000495186.1 *300205 #300960 MEND SYNDROME; MEND
#302960 CHONDRODYSPLASIA PUNCTATA 2, X-LINKED DOMINANT; CDPX2
(Continues)
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EPHB4 ENST00000358173.3 *600011 #617300 LYMPHATIC MALFORMATION 7; LMPHM7
FAT4 ENST00000394329.3 *612411 #615546 VAN MALDERGEM SYNDROME 2; VMLDS2;
#616006 HENNEKAM LYMPHANGIECTASIA–LYMPHEDEMA SYNDROME 2; HKLLS2
FLT4 ENST00000261937.6 *136352 #602089 HEMANGIOMA, CAPILLARY INFANTILE;
#153100 LYMPHEDEMA, HEREDITARY, IA; LMPH1A
FOXC2 ENST00000320354.4 *602402 #153400 LYMPHEDEMA–DISTICHIASIS SYNDROME; LPHDST
FOXP3 ENST00000376207.4 *300292 #304790 IMMUNODYSREGULATION, POLYENDOCRINOPATHY, AND 
ENTEROPATHY, X-LINKED; IPEX
FUCA1 ENST00000374479.3 *612280 #230000 FUCOSIDOSIS
GAA ENST00000302262.3 *606829 #232300 GLYCOGEN STORAGE DISEASE II; GSD2
GALC ENST00000261304.2 *606890 #245200 KRABBE DISEASE
GALNS ENST00000268695.5 *612222 #253000 MUCOPOLYSACCHARIDOSIS, TYPE IVA; MPS4A
GBA ENST00000327247.5 *606463 #230800 GAUCHER DISEASE, TYPE I
#230900 GAUCHER DISEASE, TYPE II
#608013 GAUCHER DISEASE, PERINATAL LETHAL
GBE1 ENST00000429644.2 *607839 #232500 GLYCOGEN STORAGE DISEASE IV; GSD4;
GLA ENST00000218516.3 *300644 #301500 FABRY DISEASE
GLB1 ENST00000307363.5 *611458 #230500 GM1-GANGLIOSIDOSIS, TYPE I;
#230600 GM1-GANGLIOSIDOSIS, TYPE II;
#230650 GM1-GANGLIOSIDOSIS, TYPE III;
#253010 MUCOPOLYSACCHARIDOSIS, TYPE IVB; MPS4B
GM2A ENST00000357164.3 *613109 #272750 GM2-GANGLIOSIDOSIS, AB VARIANT
GNPTAB ENST00000299314.7 *607840 #252500 MUCOLIPIDOSIS II ALPHA/BETA;
#252600 MUCOLIPIDOSIS III ALPHA/BETA
GNPTG ENST00000204679.4 *607838 #252605 MUCOLIPIDOSIS III GAMMA
GNS ENST00000258145.3 *607664 #252940 MUCOPOLYSACCHARIDOSIS, TYPE IIID; MPS3D
GUSB ENST00000304895.4 *611499 #253220 MUCOPOLYSACCHARIDOSIS, TYPE VII; MPS7
HADHA ENST00000380649.3 *600890 #609015 MITOCHONDRIAL TRIFUNCTIONAL PROTEIN DEFICIENCY; MTPD
#609016 LONG-CHAIN 3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY
HBA1 ENST00000320868.5 *141800 #301040 ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, X-LINKED; 
ATRX
HBA2 ENST00000251595.6 *141850 #236750 HYDROPS FETALIS, NONIMMUNE; NIHF
HEXA ENST00000566304.5 *606869 #272800 TAY–SACHS DISEASE
HEXB ENST00000261416.11 *606873 #268800 SANDHOFF DISEASE
HFE ENST00000357618.9 *613609 #235200 HEMOCHROMATOSIS, TYPE 1
HGSNAT ENST00000379644.8 *610453 #252930 MPS IIIC; SANFILIPPO SYNDROME C; ACETYL-CoA:ALPHA-
GLUCOSAMINIDE N-ACETYLTRANSFERASE DEFICIENCY
HPS1 ENST00000325103.6 *604982 #203300 HERMANSKY–PUDLAK SYNDROME 1; HPS1
HPS3 ENST00000296051.2 *606118 #614072 HERMANSKY–PUDLAK SYNDROME 3; HPS3
HPS4 ENST00000398145.2 *606682 #614073 HERMANSKY–PUDLAK SYNDROME 4; HPS4
HPS5 ENST00000396253.3 *607524 #614074 HERMANSKY–PUDLAK SYNDROME 5; HPS5
HPS6 ENST00000299238.5 *607522 #614075 HERMANSKY–PUDLAK SYNDROME 6; HPS6
HRAS ENST00000417302.1 *190020 #218040 COSTELLO SYNDROME; CSTLO
HYAL1 ENST00000395144.6 *607071 #601492 MUCOPOLYSACCHARIDOSIS, TYPE IX; MPS9
IDS ENST00000340855.10 *300823 #309900 MPS II; HUNTER SYNDROME; IDURONATE 2-SULFATASE DEFICIENCY; 
IDS DEFICIENCY; SULFOIDURONATE SULFATASE DEFICIENCY; SIDS 
DEFICIENCY
T A B L E  1  (Continued)
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Gen Transcript OMIM DISEASE
IDUA ENST00000247933.8 *252800 #607014 MPS1-H; HURLER SYNDROME
ITGA9 ENST00000264741.5 *603963 Ma G.C. et al. Prenat Diagn. 2008 Nov;28(11):1057–63. https ://doi.org/10.1002/pd.2130.
KIF11 ENST00000260731.3 *148760 #152950 MICROCEPHALY WITH OR WITHOUT CHORIORETINOPATHY, 
LYMPHEDEMA, OR MENTAL RETARDATION; MCLMR
KLF1 ENST00000264834.4 *600599 #613673 ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE IV; CDAN4
KRAS ENST00000311936.3 *190070 #609942 NOONAN SYNDROME 3; NS3
LAMP2 ENST00000434600.2 *309060 #300257 DANON DISEASE
LAMP3 ENST00000265598.3 *605883 #614075 HERMANSKY–PUDLAK SYNDROME 6; HPS6
LBR ENST00000338179.6 *600024 #215140 REYNOLDS SYNDROME #613471; GREENBERG DYSPLASIA
#169400 PELGER–HUET ANOMALY
LIPA ENST00000336233.9 *613497 #278000 LYSOSOMAL ACID LIPASE DEFICIENCY
LMOD3 ENST00000420581.2 *616112 #616165 NEMALINE MYOPATHY 10; NEM10
LZTR1 ENST00000215739.8 *600574 #616564 NOONAN SYNDROME 10; NS10
MAN1B1 ENST00000371589.8 *604346 #614202 MENTAL RETARDATION, AUTOSOMAL RECESSIVE 15
MAN2B1 ENST00000456935.6 *609458 #248500 MANNOSIDOSIS, ALPHA B, LYSOSOMAL
MANBA ENST00000226578.8 *609489 #248510 MANNOSIDOSIS, BETA A, LYSOSOMAL
MAP2K2 ENST00000262948.5 *601263 #115150 CARDIOFACIOCUTANEOUS SYNDROME 1; CFC1
MAP2K1 ENST00000307102.5 *176872 #615279 CARDIOFACIOCUTANEOUS SYNDROME 3; CFC3
MCOLN1 ENST00000264079.10 *605248 #252650 MUCOLIPIDOSIS IV
MFSD8 ENST00000296468.3 *611124 # 610,951. CEROID LIPOFUSCINOSIS, NEURONAL, 7; CLN7
NAGA ENST00000396398.7 *104170 # 609,241 SCHINDLER DISEASE, TYPE I
#609242 KANZAKI DISEASE
NAGLU ENST00000225927.6 *252920 #609701 MPS IIIB; SANFILIPPO SYNDROME B; N-ACETYL-ALPHA-D-
GLUCOSAMINIDASE DEFICIENCY; NAGLU DEFICIENCY
NEU1 ENST00000375631.4 *608272 #256550 NEURAMINIDASE DEFICIENCY
NF1 ENST00000358273.4 *613113 #162200 NEUROFIBROMATOSIS, TYPE I; NF1
NPC1 ENST00000269228.9 *607623 #257220 NIEMANN-PICK DISEASE, TYPE C1
NPC2 ENST00000555619.5 *601015 #607625 NIEMANN-PICK DISEASE, TYPE C2
NRAS ENST00000369535.4 *164790 # 613,224 NOONAN SYNDROME 6; NS6
PEX1 ENST00000248633.8 *602136 #214100 PEROXISOME BIOGENESIS DISORDER 1A (ZELLWEGER)
#234580 PEROXISOME BIOGENESIS DISORDER 1B #601539; HEIMLER SYNDROME 
1
PEX10 ENST00000288774.7 *602859 #614870 PEROXISOME BIOGENESIS DISORDER 6A (ZELLWEGER)
#614871 PEROXISOME BIOGENESIS DISORDER 6B
PEX11B ENST00000369306.7 *603867 #614920 PEROXISOME BIOGENESIS DISORDER 14B
PEX12 ENST00000225873 *601758 #614859 PEROXISOME BIOGENESIS DISORDER 3A (ZELLWEGER)
#266510 PEROXISOME BIOGENESIS DISORDER 3B
PEX13 ENST00000295030.5 *601789 #614883 PEROXISOME BIOGENESIS DISORDER 11A (ZELLWEGER)
#614885 PEROXISOME BIOGENESIS DISORDER 11B
PEX14 ENST00000356607.8 *601791 #614887 PEROXISOME BIOGENESIS DISORDER 13A (ZELLWEGER)
PEX16 ENST00000241041.7 *603360 #614877 PEROXISOME BIOGENESIS DISORDER 8B
#614876 PEROXISOME BIOGENESIS DISORDER 8A (ZELLWEGER)
PEX19 ENST00000368072.9 *600279 #614886 PEROXISOME BIOGENESIS DISORDER 12A (ZELLWEGER)
PEX2 ENST00000357039.8 *170993 #614867 PEROXISOME BIOGENESIS DISORDER 5B
#614866 PEROXISOME BIOGENESIS DISORDER 5A (ZELLWEGER)
PEX26 ENST00000329627.11 *608666 #614872 PEROXISOME BIOGENESIS DISORDER 7A (ZELLWEGER)
#614873 PEROXISOME BIOGENESIS DISORDER 7B
T A B L E  1  (Continued)
(Continues)
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PEX3 ENST00000367591.4 *603164 #614882 PEROXISOME BIOGENESIS DISORDER 10A (ZELLWEGER)
#617370 PEROXISOME BIOGENESIS DISORDER 10B
PEX5 ENST00000412720.6 *600414 #616716 RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, TYPE 5
#202370 PEROXISOME BIOGENESIS DISORDER 2B
#214110 PEROXISOME BIOGENESIS DISORDER 2A (ZELLWEGER)
PEX6 ENST00000304611.12 *601498 #614863 PEROXISOME BIOGENESIS DISORDER 4B
#614862 PEROXISOME BIOGENESIS DISORDER 4A (ZELLWEGER)
PEX7 ENST00000318471.4 *601757 #215100 RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, TYPE 1;
#614879 PEROXISOME BIOGENESIS DISORDER 9B
PIEZO1 ENST00000301015.9 *611184 #194380 DEHYDRATED HEREDITARY STOMATOCYTOSIS 1 WITH OR WITHOUT 
PSEUDOHYPERKALEMIA AND/OR PERINATAL EDEMA; DHS1
#616843 LYMPHEDEMA, HEREDITARY, III; LMPH3
PIK3CA ENST00000263967.3 *171834 #602501 MEGALENCEPHALY-CAPILLARY MALFORMATION-POLYMICROGYRIA 
SYNDROME; MCAP
PMM2 ENST00000268261.4 *601785 #212065 CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ia; CDG1A
PPT1 ENST00000433473.3 *600722 #256730 CEROID LIPOFUSCINOSIS, NEURONAL, 1
PSAP ENST00000394936.7 *176801 #610539 GAUCHER DISEASE, ATYPICAL, DUE TO SAPOSIN C DEFICIENCY
#249900 METACHROMATIC LEUKODYSTROPHY DUE TO SAPOSIN B DEFICIENCY
#611721 COMBINED SAPOSIN DEFICIENCY
PTPN11 ENST00000351677.2 *176876 #163950 NOONAN SYNDROME 1; NS1; # 151,100. LEOPARD SYNDROME 1; LPRD1
RAF1 ENST00000251849.4 *164760 #611553 NOONAN SYNDROME 5; NS5
RASA1 ENST00000456692.2 *139150 #608354. CAPILLARY MALFORMATION-ARTERIOVENOUS MALFORMATION; 
CMAVM
# 608,355 PARKES WEBER SYNDROME; PKWS
RIT1 ENST00000368323.3 *609591 #615355 NOONAN SYNDROME 8; NS8
RPL15 ENST00000307839.5 *604174 #615550 DIAMOND-BLACKFAN ANEMIA 12; DBA12
RYR1 ENST00000359596.3 *180901 Lethal multiple pterygium syndrome; Kariminejad et al. BMC Musculoskeletal Disorders 
(2016) 17:109
SGSH ENST00000326317.10 *605270 #252900 MPS IIIA; SANFILIPPO SYNDROME A; HEPARAN SULFATE SULFATASE 
DEFICIENCY; SULFAMIDASE DEFICIENCY
SHOC2 ENST00000369452.4 *602775 #607721 NOONAN SYNDROME-LIKE DISORDER WITH LOOSE ANAGEN HAIR 1; 
NSLH1
SLC17A5 ENST00000355773.5 *604322 #604369 SALLA DISEASE
#269920 INFANTILE SIALIC ACID STORAGE DISEASE
SLC22A5 ENST00000435065.6 *603377 #212140 CARNITINE DEFICIENCY, SYSTEMIC PRIMARY
SMPD1 ENST00000342245.8 *607608 #257200 NIEMANN-PICK DISEASE, TYPE A
#607616 NIEMANN-PICK DISEASE, TYPE B
SOS1 ENST00000426016.1 *182530 #610733 NOONAN SYNDROME 4; NS4
SOS2 ENST00000216373.5 *601247 #616559 NOONAN SYNDROME 9; NS9
SOX18 ENST00000340356.7 *601618 #607823 HYPOTRICHOSIS-LYMPHEDEMA-TELANGIECTASIA SYNDROME; HLTS
#137940 HYPOTRICHOSIS-LYMPHEDEMA-TELANGIECTASIA-RENAL DEFECT 
SYNDROME; HLTRS
SPRED1 ENST00000299084.4 *609291 #611431 LEGIUS SYNDROME; LGSS
SUMF1 ENST00000272902.9 *607939 #272200 MULTIPLE SULFATASE DEFICIENCY
TALDO ENST00000319006.3 *602063 #606003 TRANSALDOLASE DEFICIENCY
THSD1 ENST00000349258.4 *616821 #236750 HYDROPS FETALIS, NONIMMUNE; NIHF
TPP1 ENST00000299427.10 *607998 #204500 CEROID LIPOFUSCINOSIS, NEURONAL, 2
UROS ENST00000368797.8 *606938 #263700 PORPHYRIA, CONGENITAL ERYTHROPOIETIC
VEGFC ENST00000280193.2 *601528 #615907 LYMPHEDEMA, HEREDITARY, ID; LMPH1D
T A B L E  1  (Continued)
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2 |  CASE REPORT
This female premature infant was delivered via emergency 
cesarean at 30  +  1  weeks GA (weight 1,400  g (P50), first 
measured on day 3 of life, length 40  cm (P50), head cir-
cumference 28.5 cm (P58), as the result of rapidly develop-
ing NIHF (first diagnosed at 30 + 0 weeks GA) to a healthy 
mother with no consanguinity in the family history. In former 
prenatal screenings, there had been the suspicion of a con-
genital cardiac defect but no signs of increased nuchal trans-
lucency, polyhydramnios or short femur, otherwise typical of 
Noonan syndrome.
The Apgar score was 1/3/4, umbilical artery pH was 7.33. 
The patient was born with NIHF, hypovolemic shock, severe 
anemia (hemoglobin 7.7 g/dl), severe thrombocytopenia (8/
nl), and disseminated intravascular coagulation. At imme-
diate drainage of both pleural and the peritoneal cavities, 
bloody effusions were observed. After stabilization with 
fluid and catecholamine rescue, the patient was transferred 
to our NICU. Physical examination revealed muscular hypo-
tonia and a distinct short and webbed neck. Unilateral infarc-
tion and bilateral intraventricular hemorrhage grade II was 
detected on ultrasound. Echocardiography confirmed a dou-
ble–outlet right ventricle in combination with an atrial sep-
tum defect with left-right shunt. During the first few weeks 
the infant was mechanically ventilated and had bilateral chest 
tube drainage for chylothoraces. We excluded bacterial or 
viral infection, coagulation disorders and alloimmune, and 
familial thrombocytopenia, respectively. Genetic testing by 
the hydrops panel especially developed for NIHF detected a 
de novo gain of function mutation in exon 3 of the PTPN11 
gene (c.218C>T; (p.Thr73Ile)). A mutation was not detected 
in parental blood. Research of literature revealed only few 
cases of the same mutation – our case is the only one present-
ing as NIHF (Table 2).
3 |  CLINICAL COURSE
The infant was mechanically ventilated until the day of life 
22. Because of a hypertrophic cardiomyopathy, proprano-
lol therapy was started. A persistent ductus arteriosus was 
stented to keep it open.
Due to recurrent pleural effusions chest tubes were placed 
repeatedly until the age of 197 days. The infant developed a 
(sub-) ileus. A laparoscopy revealed a giant Meckel's diver-
ticulum, but no stenosis.
Since birth, the infant showed persistent severe thrombocy-
topenia requiring weekly platelet transfusions up to the present 
(Figure 1). So far no blasts that suggest a transient myelop-
roliferation syndrome or juvenile myelomonocytic leukemia 
(JMML) have been detected in peripheral blood smear. Bone 
marrow aspiration was declined by the parents as well as further 
therapy for example 6-mercaptopurine mentioned by Strullu 
et al. (2014). The monocyte population is currently 18% in the 
blood count, slightly progressive over the course, but has nota-
bly declined compared to a maximum of 37% at birth.
The infant was discharged on day 264 after birth without 
additional oxygen supply.
4 |  CONCLUSION
Although a variety of prenatal presentations of Noonan syn-
drome and NIHF have been reported in literature, this is the 
first description of NIHF due to the mutation identified in our 
patient with the c.218C>T (p.Thr73Ile) variant.
By mapping out the genetic lesion that occurs in this pa-
tient, a hematological risk stratification in NS can be per-
formed. The c.218C>T (p.Thr73Ile) is already described in 
the literature with comparable hematological neonatal pro-
cesses but so far without hydrops (Kratz et al., 2005). Strullu 





defect Thrombocytopenia NIHF Outcome
Myeloproliferative 
disorder Year
Christensen, Yaish, Leon, Sola-
Visner, and Agrawal (2013)
38 None Yes None Alive None 2013
Nunes et al. (2012) 39 Yes Yes None Alive None 2012
Bufalino, Carrera, Carlos, and 
Coletta (2010)
n.d. Yes n.d. None Alive n.d. 2010
Kratz et al. (2005) n.d. n.d. n.d. n.d. n.d. MPD (2), JMML 
none
2005
Kosaki, Suzuki, and Muroya (2002) 39 None n.d. None Alive n.d. 2002
Musante et al. (2003) n.d. n.d. n.d. n.d. n.d. n.d. 2002
Tartaglia et al. (2002) n.d. n.d. n.d. n.d. n.d. n.d. 2002
Our case 30 + 1 Yes Yes Yes Alive None 2018
Abbreviations: JMML, Juvenile Myelomonocytic Leukemia; MPD, Myeloproliferative Disorder; n.d., not denoted.
   | 7 of 8SCHÖNFELD Et aL.
et al. published four comparable patients, ranging in age from 
birth to the 90th day of life. The follow-up time is given as 
3.4 years. The c.218C>T (p.Thr73Ile) is thereby associated 
with solid tumors (e.g., neuroblastoma) and amegakaryocy-
tosis (Strullu et al., 2014).
In the literature, a case reported by Shenoy et al. with 
myelodysplastic syndrome and transformation into AML 
with consecutive stem cell transplantation can also be found 
(Shenoy et al., 2019).
Patients reporting with this germline mutation partly have 
a heart defect; all show persistent severe thrombocytopenia 
and a few juvenile myelomonocytic leukemia. Patients with a 
c.218C>T (p.Thr73Ile) mutation are at higher risk of develop-
ing myeloproliferative diseases/JMML during the first 5 years 
of life (Ganapathi, Schafernak, & Rao, 2015). The clinical 
course in this early state is milder and more often associated 
with spontaneous remission than in later years of age (Strullu 
et al., 2014).
The mechanism by which thrombocytopenia develops in 
patients with Noonan Syndrome is not entirely understood 
(Zenker et al., 2004).
In patients with severe congenital hemorrhagic disorder, 
persistent thrombocytopenia and congenital heart defect, the 
medical history and a careful clinical examination can lead to 
the diagnosis of NS. RASopathies are probably overlooked in 
cases of early lethality or in patients hospitalized in neonatal 
or pediatric intensive care units (Jhang, 2016).
The diagnosis of our patient was rapidly confirmed by the 
hydrops panel.
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